Moleculin Biotech (MBRX) Corporate presentation summary

Executive leadership and experience

• Leadership team includes experienced executives with backgrounds in drug development and multiple FDA approvals.

• Over $200 million invested by management and 200 years of combined drug development experience.

Technology and clinical pipeline

• Lead asset Annamycin is a patented, next-generation anthracycline designed to avoid cardiotoxicity and multidrug resistance.

• Annamycin is in advanced clinical development for relapsed/refractory AML, with additional studies in soft tissue sarcoma and planned trials in pancreatic cancer.

• Pipeline includes other oncology and antiviral candidates, such as WP1066 and WP1122, with ongoing preclinical and clinical studies.

Clinical efficacy and safety

• Annamycin demonstrates superior efficacy in R/R AML, with pooled complete remission rates up to 50% and no detected cardiotoxicity in over 100 patients, even at high cumulative doses.

• MIRACLE Phase 3 trial interim results show both Annamycin arms outperforming control on primary and secondary endpoints, with no safety signals.

• Efficacy is maintained in high-risk and venetoclax-pretreated populations, with durable responses and high rates of MRD negativity.